NAVLIN by EVERSANA is a single, integrated platform that combines data, software and insights to answer your most challenging price and access questions.
We help you plan and evaluate strategies to achieve success in U.S. and global markets.
NAVLIN by EVERSANA delivers a single easy-to-use platform that integrates highly accurate price and access data, software and insights to drive exponential value in the life sciences.
NAVLIN Price & Access Data is the industry’s most comprehensive, highly accurate database of global price and market access intelligence, providing the right answers to the right questions to inform your strategy at launch and beyond.
NAVLIN Price & Access Software provides the most accurate and comprehensive enterprise software solution to address global pricing challenges for pharmaceutical manufacturers.
NAVLIN Insights is the only digital platform and policy tracker that unifies all your market access metrics, insights, and progress—eliminating data silos, manual reporting, and communication gaps to clearly demonstrate your portfolio’s commercial impact.
NAVLIN Daily keeps you up to date and informed by connecting the dots on how the day’s biggest stories affect your business. Experience global price and market access news without all the noise.
NAVLIN Revenue Management brings together all critical revenue management operations, along with the power of NAVLIN Price & Access Data, to deliver efficient, intuitive, accurate and compliant tracking and reporting – all in one innovative & integrated digital platform.
NAVLIN Insights is the only digital platform and policy tracker that unifies all your market access metrics, insights, and progress—eliminating data silos, manual reporting, and communication gaps to clearly demonstrate your portfolio’s commercial impact.
NAVLIN Insights KPI is the only digital platform that measures and showcases your market access success across every brand in your portfolio – helping you deliver and communicate the commercial impact of your portfolio.
From NAVLIN by EVERSANA, the most trusted name in price & market access.
Stay ahead in a rapidly changing policy environment with the MFN Tracker from NAVLIN Insights. This subscription-based resource delivers weekly updates on market trends, launch strategies, pricing shifts, and payer reactions—giving you the clarity and confidence to make informed decisions.
Join the growing number of executives leveraging MFN Tracker to navigate uncertainty and drive results. Subscribe now to unlock actionable market intelligence and stay ahead of the curve.
From continuous discovery to submission and post-award tracking — NAVLIN by EVERSANA industrializes every step of the tender lifecycle with AI, delivering faster decisions, stronger margins, and scalable compliance across 70+ markets.
NAVLIN by EVERSANA delivers a single easy-to-use platform that integrates highly accurate price and access data, software and insights to drive exponential value in the life sciences.
NAVLIN Price & Access Data is the industry’s most comprehensive, highly accurate database of global price and market access intelligence, providing the right answers to the right questions to inform your strategy at launch and beyond.
NAVLIN Price & Access Software provides the most accurate and comprehensive enterprise software solution to address global pricing challenges for pharmaceutical manufacturers.
NAVLIN Insights is the only digital platform and policy tracker that unifies all your market access metrics, insights, and progress—eliminating data silos, manual reporting, and communication gaps to clearly demonstrate your portfolio’s commercial impact.
NAVLIN Daily keeps you up to date and informed by connecting the dots on how the day’s biggest stories affect your business. Experience global price and market access news without all the noise.
NAVLIN Revenue Management brings together all critical revenue management operations, along with the power of NAVLIN Price & Access Data, to deliver efficient, intuitive, accurate and compliant tracking and reporting – all in one innovative & integrated digital platform.
NAVLIN Insights is the only digital platform and policy tracker that unifies all your market access metrics, insights, and progress—eliminating data silos, manual reporting, and communication gaps to clearly demonstrate your portfolio’s commercial impact.
NAVLIN Insights KPI is the only digital platform that measures and showcases your market access success across every brand in your portfolio – helping you deliver and communicate the commercial impact of your portfolio.
From NAVLIN by EVERSANA, the most trusted name in price & market access.
Stay ahead in a rapidly changing policy environment with the MFN Tracker from NAVLIN Insights. This subscription-based resource delivers weekly updates on market trends, launch strategies, pricing shifts, and payer reactions—giving you the clarity and confidence to make informed decisions.
Join the growing number of executives leveraging MFN Tracker to navigate uncertainty and drive results. Subscribe now to unlock actionable market intelligence and stay ahead of the curve.
From continuous discovery to submission and post-award tracking — NAVLIN by EVERSANA industrializes every step of the tender lifecycle with AI, delivering faster decisions, stronger margins, and scalable compliance across 70+ markets.
650+
+99%
<24
4,000+
24x7
99.5%
Henan province has led an inter-provincial drug procurement round with 34 drug varieties up for bidding. A total of 130 pharmaceutical firms were selected across 269 drug specificationsThe variety groups were split into competitive high-quality drugs (Group A) and lower-priced options (Group B)The procurement batch involved 32 provinces, municipalities, and regions across China, including heavyweights like Beijing, Shanghai, and Guangdong
The overall impact of TrumpRx appears limited based on the first few months of the program, according to new reporting from POLITICOAccording to a 10-Q filed by GoodRx and reviewed by POLITICO, the discount drug retailer has not noticed a material impact on its business from the programEarly demand has been concentrated in GLP-1 therapies, though GoodRx said the program’s longer-term impact remains uncertain as MFN pricing and direct-to-consumer drug access expand
Last week, NAVLIN Daily brought you key market access developments from across the globeChina advanced its latest round of volume-based procurement, while Spain enacted Law 3/2026, making drug pricing and reimbursement agreements confidentialMeanwhile, South Korea introduced new drug pricing standards on August 1, lowering generic price reductions and adjusting multi-item listing rules
AIFA’s new Scientific and Economic Committee (CSE) has cut the average pricing and reimbursement evaluation period to approximately four months, according to a new reportGeneric drugs are the fastest to process (two months), while orphan medicines take the longest (11.9 months). The four-month average is weighted heavily by the high number (56%) of generic applicationsThe report states that the full P&R pathway, from procedure start to Official Gazette publication, now averages 185 days (six to seven months). Including the pre-initiation phase, it climbs to 206 days
Bidding for China’s volume-based procurement program took place at the Nanjiao Hotel in Shanghai on Friday. After initial and revival bids were placed, officials announced that 521 products from 327 companies met the preliminary qualifications to be selectedBidding was highly competitive, with “mainstream” companies that could guarantee the supply and quality of highly regarded products preferred in this year’s selectionsJiang Changsong, assistant dean of the National Institute of Healthcare Security and director of the Price and Procurement Office, believed that the optimized price mechanism may yield only moderate overall price reductions this year compared to past batches
Spain has now enacted Law 3/2026, effective August 1, making drug pricing and reimbursement agreements formally confidentialUnder the revised legislation, financing agreements between the Ministry of Health and pharmaceutical companies, information generated through their implementation, and awarded prices in public medicine supply contracts are explicitly classified as confidentialNAVLIN Daily has been covering the ongoing legislative process extensively
In a recent interview, new G-BA Chair Dr. Sonja Optendren said that Germany could consider covering weight-loss drugs "under certain conditions"Statutory health insurance providers in Germany currently do not reimburse weight loss drugs, as they fall under lifestyle medicationsIf this policy does change, Germany would be following in the footsteps of France, which became the first country in the EU to start reimbursing modern weight-loss drugs such as Ozempic and Wegovy earlier this year
Eisai has launched Leqembi (lecanemab) in India for the treatment of early Alzheimer’s disease after receiving marketing authorization from the Central Drugs Standard Control Organization (CDSCO) Leqembi is indicated for patients with Mild Cognitive Impairment (MCI) and mild dementia due to early Alzheimer’s disease The launch comes as India faces a growing dementia burden driven by an ageing population, late diagnosis, and limited awareness
Last week, NAVLIN Daily brought you key market access developments from across the globe The U.S. administration continued advancing its multi-pronged MFN drug pricing strategy, while AstraZeneca said the evolving U.S. policy has already influenced its pricing approach France strengthened its HTA framework with the launch of a new strategic center of expertise to support evolving evaluation and market access activities
The Spanish government has removed specific price-cut percentages for generics in its draft Medicines Law, leaving the upcoming Royal Decree to finalize these detailsMeanwhile, Farmaindustria and Biosim are still calling for major changes to the proposed frameworkFarmaindustria further warned that the proposed model could trigger unsustainable price erosion if competitors substantially undercut prices without the pricing bands envisaged in the draft Medicines Law, while Biosimsaid the draft should clearly distinguish between maximum reimbursed prices, notified prices, and free market prices, arguing that medicines sold outside the National Health System should generally be subject to free pricing unless explicitly regulated
